Literature DB >> 23690054

Oseltamivir-resistant influenza viruses isolated in South Korea from 2005 to 2010.

Han-Gil Cho1, Jang-Hoon Choi, Hyun-Kyung Lee, Su-Kyoung Mun, Jong-Bok Lee, Eek-Hoon Jho, Chun Kang, Young-Hee Lim.   

Abstract

South Korean isolates of oseltamivir-resistant influenza viruses from 2005-2010 were investigated with a total 491 influenza viruses identified from 1702 specimens. Neuraminidase genes from 342 influenza viruses (71 A/H1N1, 74 pandemic A/H1N1 2009, 117 A/H3N2, and 80 B) were analyzed by RT-PCR with molecular markers for oseltamivir resistance. The H274Y mutation in the NA protein was identified in 100 % (n=40) of A/H1N1 viruses circulating in 2008-2009. Influenza A/H1N1 viruses harboring the H274Y substitution exhibited, on average, a 626-fold reduction in oseltamivir susceptibility and clustered with the A/Norway/1736/2007 strain. Close and timely monitoring for resistance to clinically available influenza antivirals should be consistently performed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23690054     DOI: 10.1007/s00705-013-1734-3

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  2 in total

Review 1.  Single enzyme nanoparticle, an effective tool for enzyme replacement therapy.

Authors:  Dong Hyun Kim; Han Sol Lee; Tae-Wan Kwon; Young-Min Han; Nae-Won Kang; Mee Yeon Lee; Dae-Duk Kim; Myeong Gyu Kim; Jae-Young Lee
Journal:  Arch Pharm Res       Date:  2020-01-27       Impact factor: 4.946

2.  3D-quantitative structure-activity relationship and antiviral effects of curcumin derivatives as potent inhibitors of influenza H1N1 neuraminidase.

Authors:  Yanni Lai; Yiwen Yan; Shanghui Liao; Yun Li; Yi Ye; Ni Liu; Fang Zhao; Peiping Xu
Journal:  Arch Pharm Res       Date:  2020-04-04       Impact factor: 4.946

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.